Pharmacological treatment of ectopic pregnancy: Accuracy, safety and cost‐effectiveness of day 1–7 β‐hCG measurements
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15511 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Adi Dayan-Schwartz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel. Hauptthemen laut MEDLINE: Methotrexate, Pregnancy, Ectopic, Cost-Benefit Analysis, Chorionic Gonadotropin, beta Subunit, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The aim of the present study was to compare accuracy, safety and cost‐effectiveness of three β‐hCG measurements protocols, applied in managing ectopic pregnancies (EP) with methotrexate (MTX): (1) day 1 to 7 β‐hCG levels, (2) day 1 to 4 β‐hCG levels and (3) day 4 to 7 β‐hCG levels.
Methods
Cost‐minimization analysis (CMA) based on a retrospective study of patients treated with single‐dose MTX for EP, was evaluated at a single institution between January 2001 to May 2021. Successful MTX treatment was defined as no surgical intervention. We evaluated safety by analyzing cases of day 4 interventions and cases of inconsistency between the different protocols. Predicting accuracy was assessed by the area under the receiver operating characteristic (AUC) curve.
Results
A total of 229 patients with single dose MTX treatment were included. Overall, 184 (80.3%) patients were treated successfully with a single dose of MTX. For days 1 and 7 the optimal cutoff point was 7% reduction in β‐hCG levels with sensitivity, specificity and PPV of 76.6% (69.9–82.5, 95% CI), 75.5% (60.5–87.1, 95% CI) and 92.8% (88.4–95.6, 95% CI), respectively. There was no significant difference between the protocols' AUC. None of the patients had any change of management during their day 4 visit in our 20 years of records. The cost for each visit day (day 4 and 7) was calculated with a total cost of 251 USD per patient.
Conclusion
Patients treated with MTX for EP, measurement of day 1 and day 7 β‐hCG serum levels has a cost minimization advantage and is not inferior to the traditional protocol for predictive accuracy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel.
- Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Department of Human Biology, University of Haifa, Haifa, Israel.
ORCID-Profile: Adi Dayan-Schwartz
Zitieren
APA
Dayan-Schwartz, A., Abd Elgani, S., Abdul-Ghani, T., Kogan, L., Reiss, A., & Tal, A. (2024). Pharmacological treatment of ectopic pregnancy: Accuracy, safety and cost‐effectiveness of day 1–7 β‐hCG measurements. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15511
Vancouver
Dayan-Schwartz A, Abd Elgani S, Abdul-Ghani T, Kogan L, Reiss A, Tal A. Pharmacological treatment of ectopic pregnancy: Accuracy, safety and cost‐effectiveness of day 1–7 β‐hCG measurements. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15511
BibTeX
@article{DayanSchwartz2024,
author = {Dayan-Schwartz, Adi and Abd Elgani, Suzan and Abdul-Ghani, Tamam and Kogan, Liron and Reiss, Ari and Tal, Alon},
title = {Pharmacological treatment of ectopic pregnancy: Accuracy, safety and cost‐effectiveness of day 1–7 β‐hCG measurements},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15511}
}
EUVIMED